MiR-24-3p as a prognostic indicator for multiple cancers: From a meta-analysis view

Authors:

1. He Wang†, Department of Urology, First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou 215006, China, sdwh0326@163.com

2. Chunyang Chen†, Department of Urology, First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou 215006, China, 18862238857@163.com

3. Keke Ding, Department of Urology, First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou 215006, China, dingkekeyouxiang@163.com

4. Weijie Zhang, the corresponding author, Department of Urology, First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou 215006, China, zhangweijie@suda.edu.cn

5. Jianquan Hou, the corresponding author, Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi RD, Suzhou 215006, China, sdfyyhou123@163.com

He Wang† and Chunyang Chen† contributed equally to this work and shall share first authorship

Corresponding author:

Weijie Zhang, E-mail: zhangweijie@suda.edu.cn, Tel: +86 18362724272

Jianquan Hou, E-mail: sdfyyhou123@163.com, Tel: +86 18906210606
Abstract

A growing number of researches suggests that microRNAs (miRNAs) as oncogene or tumor suppressor genes play a fundamental role in various kinds of cancers. Among them, miR-24-3p, as a star molecule, is widely studied. However, the prognostic value of miR-24-3p is unclear and controversial. We conducted this meta-analysis to evaluate the prognostic value of miR-24-3p in a variety of cancers by integrated existing articles from four databases. Materials and Methods. PubMed, Embase, Web of Science, and Cochrane Library (last update in March 2020) were searched for approach literature. Hazard ratios (HRs) and odds ratios (ORs) were used to evaluate the association between miR-24-3p expression levels and prognostic value or clinicopathological characteristics, respectively. Results. A total of 15 studies from 14 literature were finally qualified and concluded in the present meta-analysis. A significantly worse overall survival was observed in higher expression of miR-24-3p cancer group for OS (Overall survival) of log-rank tests and Cox multivariate regression by fixed effects model. Also, we found a significant correlation between elevated miR-24-3p levels to RFS (Recurrence-free survival) and DFS (Disease-free survival). In addition, the pooled odds ratios (ORs) showed that evaluated miR-24-3p was also associated with the larger tumor size (≥5cm) and advanced TNM stage (III and IV). Conclusion. Built on the above findings, elevated expression levels of miR-24-3p may serve as a promising biomarker used to predict the worse prognosis of cancer patients.

Keywords: MiR-24-3p, Human carcinoma, Prognosis, Clinical characteristics, Meta-analysis

Background

MicroRNAs (miRNAs), a kind of endogenous non-coding RNAs of 18–22 nucleotides in length, negatively regulate target genes expression at post-transcriptional level [1-3]. As either oncogenes or anti-oncogenes, they are found to play vital roles in a wide range of fundamental biological processes, such as proliferation[4, 5], differentiation[6,
7], apoptosis[8, 9], cell cycle[10-13], metastasis[14-16], stress response[17-19], metabolic[20-22] and etc. Owing to its detectability and stability in tissues, marrow or blood, a growing number of studies suggests that miRNAs can serve as promising biomarkers for the prognosis of carcinomas[23].

MiR-24-3p (used name was miR-24), a master regulator from the gene cluster of miR-23a–24-27a, has been identified as an onco or oncosuppressor-miR and its expression is closely associated with cancer occurrence and development by recent studies[24, 25]. Previous studies showed that miR-24-3p was highly expressed in many carcinomas[26, 27]. In addition, the evaluated expression of miR-24-3p was also found to be associated with cancer prognosis and tumor clinicopathological features, but there were some opposite consequences[28, 29]. Up to now, a number of studies have been investigated this molecule in many kinds of cancer, but the most individual study has their limits, for example, small sample size or obtaining controversial results, and so on.

Accordingly, to explore the clinical prognostic value of miR-24-3p in various cancers, we performed this systematic review and meta-analysis to give a better understanding.

**Methods**

**Literature search strategy**

In this meta-analysis, the statement was used as a guideline[30]. We performed a literature search using the online databases, including PubMed, Embase, Web of Science (WOS) and Cochrane Library from inception to March 2020. The terms “miR-24 OR microRNA-24 OR miRNA-24 OR miR24” and “cancer OR tumor OR neoplasm OR carcinoma OR malignancy” were used to determine the correlative literature.

**Inclusion and exclusion criteria**

The inclusion criteria were: (1) studies were published in English; (2) miR-24-3p was
investigated in carcinomas; (3) studies were identified the correlation between miR-24-3p expression levels and the prognosis of cancer patients; and (4) studies were provided hazard ratio (HR) and its corresponding 95% confidence intervals (CIs) or sufficient data which can further to assess its HR. The exclusion criteria: (1) studies were published in non-English; (2) studies were case report, abstracts, reviews, letters or meta-analysis; (3) studies were not relevant to the prognostic of cancer patients or the prognosis data originated from TCGA; or (4) studies did not offer sufficient data to calculate the HRs and 95% CI.

Data extraction
Built on the above criteria, all included studies were managed separately by two investigators (H Wang and CY Chen) and any disagreement were further examined by a third author (KK Ding). The following characteristics were collected: the first author's name, year of publication, nationality, cancer type, specimen, method of detection, sample size, type of miRNA, outcome, tumor stage, lymph node metastasis, cut-off value, follow-up time, HR and its corresponding 95% CI. Moreover, the clinicopathological parameter data were also collected from qualified articles. For studies which not provide HR and 95% CI, the data were extracted from the Kaplan-Meier curves via Engauge Digitizer version 4.1[31]. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the pooled studies. High quality required a NOS score ≥ 5.

Statistical analysis
The present meta-analysis was assessed by Stata SE12.0 software, RevMan5.2 software and Engauge Digitizer 4.1 software. Pooled HRs with their CIs were applied to describe the correlation between the expression of miR-24-3p and relevant survival outcome (OS, DFS, RFS), and the relation between miR-24-3p and relevant clinicopathologic features were also described by pooled odds ratios (ORs) and their CIs. The heterogeneity was evaluated by $I^2$ statistics and Q tests. $P < 0.05$ and / or $I^2 >$
50% were defined as significant heterogeneity and random effects model was further used. In addition, a sensitivity analysis was used to evaluate the contribution of each study to the pooled HR and we could further to estimate the stability of the consequence. Finally, we evaluate the potential publication bias by funnel plot, Begg’s test and Egger’s test. P < 0.05 was known as obvious publication bias[32].

Results

As is shown in figure 1, 1099 literatures were obtained from online databases PubMed, Embase, Web of science (WOS) and Cochrane library. After removing the duplicates, abstract, review, case report, meta-analysis, studies which were not written in English and unrelated researches, 86 articles were subsequently full-text review. Among these, 71 articles were further to removed according to these criteria: studies not on patient (n = 2), studies without survival data (n = 45), survival data from TCGA (n = 5), multiple miRNAs (n = 1), or insufficient data (n = 19). Eventually, a total of 15 studies from 14 articles were included. (Table 1). The overall sample size is 1518 patients coming from 25 to 247 which from 4 countries. Among these studies, several types of cancer include lung cancer (n = 3)[33-35], hepatocellular carcinoma (n = 2)[36, 37], colorectal cancer (n = 2)[29, 38], nasopharyngeal carcinoma (n = 2)[39, 40], osteosarcoma (n = 1)[41], ALL (n = 1)[42], AML (n = 1)[42], advanced gastric cancer (n = 1)[28], esophageal cancer (n = 1)[43], head and neck squamous cell carcinoma (n = 1)[44]. As for OS, RFS and DFS, there were seven studies directly provide HRs and its 95% CI [28, 29, 35-39]. In addition, the remaining eight studies only provided Kaplan-Meier curves[28, 33, 34, 40-44]. All studies measured the miR-24-3p expression level by qRT-PCR (quantitative real-time polymerase chain reaction).

The association between miR-24-3p expression levels and the overall survival (OS)
Ten enrolled articles including eleven studies and 1212 patients were used to investigate the correlation between miR-24-3p expression levels and the OS by using log-rank tests and presented the data of univariate. Generally, a significant correlation between miR-24-3p levels and OS (HR = 1.609, CI: 1.291–2.004, Figure. 2a). However, an obvious heterogeneity was also observed (I² = 85.20%, P ≤ 0.001, Table 2). Hence, the random effects model was followed in succession but the significance was disappeared (HR = 1.507, CI: 0.810-2.803, Table 2), indicating that the heterogeneity significantly influenced the consequence.

To explore the source of the heterogeneity, the sensitivity analysis was performed, but there was also no positive consequence (Figure. 2c). Subsequently, funnel plots, Begg’s test and Egger’s test were implemented to assess the potential publication bias and two studies as the outliers were identified eventually (Figure. 2d) (Liu et al.[41] and Gao et al.[29]). After removing them, dramatically decline of the heterogeneity was observed (I² = 34.60%, P = 0.141) in the overall analysis, and the significance of the prognostic effects of miR-24-3p expression was still obvious (Figure. 2b). Finally, to further explore the source of the heterogeneity, subgroup analyses were applied by factors including population (Asian(Chinese) and Non-Asian), sample size (≥100 and <100), NOS scores (≥8 and <8), specimen (tissue and non-tissue) tumor category 1 (solid tumor and non-solid tumor), tumor category 2 (digestive system and non-digestive system) and tumor (oesophageal cancer, osteosarcoma, lung cancer, gastric cancer, colorectal cancer, ALL, AML and hepatocellular carcinoma)(Table 2). As a consequence, the heterogeneity was controlled successfully in six subgroups and all them have significant correlations: 1). The subgroup of non-Asian (HR = 2.615, CI: 1.668–4.099; I² = 0.000%, P = 0. 693, Figure. 3a). 2). The specimen derived from non-tissue (HR = 2.399, CI: 1.659–3.470; I² = 0.000%, P = 0.949, Figure. 3d). 3) The sample size greater than or equal to 100 (HR = 2.779, CI:2.051–3.766; I² = 0.000%, P = 0.873, Figure. 3b). 4) The patients of hematologic tumor (HR = 2.425, CI: 1.491–3.944; I² = 0.000%, P = 0.751, Figure. 3e). 5). The patients of hepatocellular carcinoma (HR = 2.607, CI: 1.756-3.871; I² = 0.000%, P = 0.637). and 6). The patients of lung cancer.
In addition, significant correlations are also observed in the study of NOS score less than eight by random effects model, which were consistent with the significance of the results by fixed effects model (Table 2). Moreover, significant correlations were observed between miR-24-3p expression levels and OS in the studies with the population derived from Asian (Chinese) (HR = 1.381, CI: 1.219-2.004, Figure 3a), solid tumor (HR = 1.448, CI: 1.131-1.852, Figure. 3e), digestive system (HR = 1.705, CI: 1.291-2.253, Figure. 3f) and non-digestive system (HR = 1.461, CI: 1.021-2.090, Figure. 3f) by fixed effects model, while there were no significances identified in these groups when the random effects model was applied (Table 2). For patients of Colorectal cancer, the prognostic value of miR-24-3p expression levels to the OS was completely different (Kerimis D et al.[38] HR = 4.070, CI: 1.25-13.19; Gao Y et al.[29] HR = 0.285, CI: 0.139–0.584). Due to insufficient data, the consequence was lack of efficiency and the heterogeneity was also significant ($I^2 = 93.00\%$, $P \leq 0.001$). Therefore, more relevant studies are required to perform the analysis. Built on the above consequences, meta-regression was also used, but there was no meaningful contribution identified with impacting on the heterogeneity (Table 2).

**The independent role of miR-24-3p expression levels as a prognostic indicator**

Five studies containing 775 patients implemented the Cox multivariate regression to assess the prognostic value of miR-24-3p expression levels in carcinoma patients by adjusting other factors. The significant correlation of miR-24-3p expression levels to the OS (HR = 2.384, CI: 1.813-3.134) was observed by fixed effects model. However, the heterogeneity was relatively obvious ($I^2 = 82.30\%$, $P = 0.000$, Table 3) and the significance was vanished by random effects model (HR = 1.994, CI: 0.991-4.015). Homoplastically, Subgroup analyses were applied to reduce the heterogeneity. As a result, the homogeneity was reached within the studies of sample size greater than or equal to 100 ($I^2 = 0.000\%$, $P = 0.861$), NOS less than 8 ($I^2 = 45.50\%$, $P = 0.176$) and the patients of hepatocellular carcinoma ($I^2 = 45.50\%$, $P = 0.176$). And the significant
association was identified between miR-24-3p expression levels and OS with the sample size greater than 100 (HR = 3.369, CI: 2.414-4.701), NOS less than 8 (HR = 3.041, CI: 2.150-4.300) and the patients of hepatocellular carcinoma (HR = 3.041, CI: 2.150-4.300). In addition, the significant correlations were identified between miR-24-3p expression levels to the OS in the population from Asian(Chinese) (HR = 2.373, CI: 1.813-3.134), the specimen derived from tissue (HR = 2.448, CI: 1.804-3.323) and NOS larger than or equal eight by fixed effects model, which become to no significance within those subgroups by random effects model (Table 3). For patients of Colorectal cancer (HR = 0.752, CI: 0.212-0.978), the prognostic value of miR-24-3p expression levels to the OS was also opposite (Kerimis D et al.[38] HR = 2.60, CI: 0.780-8.660; Gao Y et al.[29] HR = 0.456, CI: 0.394-1.434). Thus, more pertinent studies are required to perform the analysis. Similarly, there was no noteworthy contribution identified to greatly influence the variation of HR by meta-regression (Table 3). But the sensitivity analysis suggested that Gao et al.[29] has a significant impact on the result (Figure. 4c). The heterogeneity was vanishing (I^2 = 0.000%, P = 0.591, Figure. 4b) by removing this outlier and the correlation of miR-24-3p expression levels to the OS was also significant (HR = 3.039, CI: 2.268-4.074, Figure. 4b). Finally, funnel plots, Begg’s test (P = 0.734) and Egger’s test (P = 0.460) indicated that there was no bias. But, the number of enrolled studies was few and more data are needed to reinforce this result.

The correlation of miR-24-3p expression levels to the RFS /DFS

Except for OS as a prognostic indicator, RFS and DFS are also be accepted as an evaluation criterion. Here, four studies reported RFS including 393 patients applied log-rank tests, while only one also utilized Cox multivariate regression. After pooling the HR, we observed a significant association between miR-24-3p expression levels to the RFS of log-rank tests (HR = 2.315, CI: 1.491-3.594, figure. 5a) by fixed effects model. However, the heterogeneities were quite obvious (I^2 = 66.70%, P = 0.290, Table 4). The random effects model was further implemented but the significance was
disappeared (HR = 1.814, CI: 0.741-4.440), indicating that the heterogeneity influenced the consequences significantly. Furthermore, owing to the limited number of statistics from Cox multivariate regression, the sensitivity analysis and publication bias were only applied to analysis with data extracted from log-rank tests. The sensitivity analysis result indicated that no studies had significant influences on the consequent (Figure. 5c). However, the investigation of potential publication bias identified an outlier (Figure. 5d, Wang S et al.[40]). After deleting this study, the heterogeneity was obvious declined ($I^2 = 45.30\%, P = 0.161$) and the significance of the correlation between miR-24-3p expression levels and the RFS was not altered (HR = 2.575, CI: 1.642-4.029, Figure. 5b). Due to the limit included studies, more data are needed to enhance the result. In addition, there were only two studies containing 226 patients revealed the DFS statistics and almost no heterogeneity in both log-rank tests and Cox multivariate regression ($I^2 = 3.600\%, P = 0.309$, $I^2 = 0.000\%, P = 0.330$, respectively, Table 4) by used a fixed effects model. We also observed significant strong correlation between miR-24-3p expression levels to the DFS of both log-rank tests (HR = 2.361, CI: 1.390-4.012) and Cox regression tests (HR = 2.313, CI: 1.315-4.067) by fixed effects model.

**Correlations between miR-24-3p levels and clinicopathological features among various carcinomas**

Six studies containing 536 patients investigated the correlation of miR-24-3p expression levels to different clinical characteristics. As showed in Table 5, miR-24-3p expression levels were significant correlation with tumor size (OR = 1.655, CI: 1.124-2.437) by the fixed effects model with lesser heterogeneity ($I^2 = 37.50\%, P = 0.184$). In addition, there were no significance identified in the correlation between age (OR = 0.684, CI: 0.357-1.310), gender (OR = 1.286, CI: 0.758-2.107), lymph node metastasis (OR = 1.591, CI: 0.758-3.339) or TNM stage (OR = 1.437, CI: 0.959-2.154) with the expression levels of miR-24-3p. There was no heterogeneity in the analysis of age ($I^2 = 0.000\%, P = 0.525$) and gender ($I^2 = 0.000\%, P = 0.842$), but the heterogeneity
of lymph node metastasis and TNM stage were obviously ($I^2 = 70.90\%, P = 0.064; I^2 = 85.50\%, P = 0.000$, respectively). To decrease the heterogeneity, sensitivity analysis and publication bias were further investigated to each of them. As a result, an outlier was found (Liu et al.[36]) in the TNM stage. After removing the outlier, the heterogeneity was dramatically decreased from 85.50% to 0.000% and the associations between high miR-24-3p expression levels to advanced TNM stage were significant ($OR = 2.328, CI: 1.490-3.637$). (Figure. 6). Moreover, there was no potential publication bias about TNM stage by funnel plot, Begg’s test ($P = 0.086$) and Egger’s test ($P = 0.734$). For the analyze of lymph node metastasis, there were only two studies and had an obvious opposite result (Pan et al.[33], OR = 2.974, CI: 1.101-8.037; Zhou et al.[35], OR = 0.725, CI: 0.238-2.208). Due to insufficient data, the consequence would be lack of efficiency and the reasons of heterogeneity were unacceptable. Thus, more pertinent studies are required to perform the analysis.

**Discussion**

It is of great importance to explore prognostic biomarkers with the patients of carcinoma as specific biomarkers can further help to directly stratify patients and effectively guide clinical decision-making. MiR-24-3p, as an oncogene or tumor suppressor, plays a key role in the occurrence, progression and metastasis of human carcinoma was realized by more and more researchers gradually[24, 25]. Quan et al. [45] had made a meta-analysis to research the correlation between miR-23a/24-2/27a cluster with human cancers, but they only had limited data to draw a conclusion that high expression levels of miR-23a/24-2/27a indicated a worse prognosis and no further analyzing the correlation between miR-24-3p expression levels to the clinicopathological characteristics. Subsequently, more and more studies which focus on the miR-24-3p expression levels with cancer progression, metastasis and prognosis of patients were carried on[4-7, 14-16]. Thus, the exact role of miR-24-3p on the clinical prognosis of patients in various human carcinomas still need to investigate.
further. In this meta-analysis, total of 15 studies including 1518 people were recruited. Among them, ten studies containing 1212 patients provided the statistics of the OS by log-rank tests. By the pooling strategy, we know that the elevated miR-24-3p expression levels were linked to worse prognosis of cancer patients. Subsequently, several approaches were put in place to investigate the heterogeneity. First, subgroup analyses were conducted to identify the potential sources of heterogeneity. We found that the heterogeneity was achieved within the non-Asian population, non-tissue, the studies of sample size greater than or equal 100, hematologic tumor, hepatocellular carcinoma and lung cancer. But it was not controlled in other groups, such as the Asian population, studies of sample size less than to 100, solid tumor and so on. Second, the sensitivity analysis was used, but no outlier was identified to impact on the pooled results significantly. Third, two studies were identified as outliers by publication bias evaluation (Liu et al.[41] and Gao et al.[29]). After retrieving the data of outliers, we found that the specimen recruited in them were all from Asian (Chinese), tissue and the sample size less than 100 which all have strong heterogeneity. Besides, Liu et al.[41] was the sole study that focused on Osteosarcoma and Gao et al.[29] had an opposite conclusion with Kerimis et al.[38] who also investigated the miR-24-3p expression levels to colorectal cancer. After removing those two outliers, greatly declined of the heterogeneity was observed. Based on the mentioned above, these two studies could be the major sources of heterogeneity. However, more relevant data are needed to further investigate because of the limit number of studies. There were five studies including 775 patients obtained the data of HRs by Cox multivariate regression. Cox multivariate regression has been known as an effective approach because it can evaluate the contribution of each factor independently by adjusting other factors[46]. Thus, the consequences by Cox multivariate regression are always considered as independent effects of each factor on the clinical outcome. As a result, we found that the significance was inconsistent among different effects model. This phenomenon suggested that the heterogeneity was relatively obvious and the consequences were instable. Through the subgroup analyses, we found that the heterogeneity was declined in hepatocellular carcinoma and achieved in the studies of sample size larger than or equal 100. In
addition, the sensitivity analysis identified one outlier, Gao et al.[29] who has an opposite conclusion with Kerimis et al[38]. After removing this study, the heterogeneity had been significantly vanished. High miR-24-3p expression had a significantly worse survival and there was no publication bias. Thus, the power of miR-24-3p expression levels might serve as an independent prognostic indicator and we need more data to reinforce this conclusion. Also, we detected additional indexes, such as RFS and DFS. MiR-24-3p expression levels were deemed to be significantly associated with DFS of statistics extracted from both log-rank tests and Cox regression analysis. For the RFS of cancer patients, only the fixed effects model revealed a significant correlation between miR-24-3p expression with this prognostic index and the heterogeneity was palpable. We identified an outlier (Wang et al.[40]) through publication bias evaluation. After removing this study, the heterogeneity was declined and the significance of the association between miR-24-3p expression levels and the RFS was not altered.

As for the clinicopathological parameters, six studies including 536 patients had evaluated the association of miR-24-3p expression levels to the distinctive clinical parameters. The over-expression of miR-24-3p was found to be significantly related to larger tumor size by the fixed effects model. Moreover, we found significant heterogeneity between miR-24-3p expression levels to TNM stage. Applying sensitivity analyses, we identified one study (Liu et al.[36]) which had great impact on the result for the TNM stage. After removing this study, the heterogeneity completely disappeared; the association between miR-24-3p expression levels to the TNM stage was also significant. In addition, there were only two studies about the lymph node metastasis are enrolled and the conclusion might be not reliable. The analyzes of clinical features of a definite carcinoma should be normalized for the cut-off values, the feature categories and so on, to enrich the enrolled cases and characteristics for the meta-analysis.

As far as we know, this meta-analysis was the most comprehensive and systematic one to explore the correlation between the miR-24-3p expression levels with the prognosis of cancer patients in depth. Subgroup analysis, meta regression, sensitivity analysis and
publication bias had been used to investigate the possible source of the heterogeneity to the greatest extent[47]. In spite of this, several flaws were hard to avoid in this meta-analysis. First, inevitable limitation from insufficient data in this analysis (only 15 studies with 1518 patients). Second, the cut-off values of the miR-24-3p expression levels were not exactly among those studies, thus, the accuracy of prognostic results may be influenced. Third, part of HRs was calculated from the survival curves which may cause some bias. Four, the number of recruited studies for DFS, RFS and clinicopathological features analyses were relatively insufficient. Taking above reasons into account, we need better designed and large sample size studies for further research before applying miR-24-3p as a prognostic biomarker of tumor in clinical applications.

**Conclusions:**

The overexpression of miR-24-3p was an underlying risk of poor prognosis in various human carcinomas, especially in hepatocellular carcinoma and lung cancer. As for other types of carcinomas, the results are not yet stable and more studies including normalized research conditions are required to identify miR-24-3p prognostic values further. In addition, high miR-24-3p expression levels were linked to the progression of cancers, developing more malignant behaviour, such as larger tumor sizes and the advanced TNM stages. To sum up, miR-24-3p expression levels could serve as a potential prognostic marker of human carcinoma.

**Abbreviations:**

WOS: Web of Science, OS: Overall survival, DFS: Disease-free survival, RFS:
Recurrence-free survival, DMFS: Distant metastasis-free survival, NOS: Newcastle-Ottawa scale scores, U: univariate, M: multivariate, qRT-PCR: Quantitative Real-time PCR, 95%CI: 95% confidence interval, Fixed: Fixed effects model, HR: hazard ratio, Random: Random pooling model, HCC: Hepatocellular carcinoma, CRC: Colorectal cancer, Advanced GC: Advanced Gastric cancer, ALL: Acute Lymphocytic Leukemia, AML: Acute Myelocytic Leukemia, NPC: Nasopharyngeal carcinoma, HNSCC: Head and neck squamous cell carcinoma, NSCLC: Non-small cell lung carcinoma.

Declarations

Ethics approval and consent to participate:
All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

Consent for publication
Not applicable.

Availability of data and material
The authors declare that all data supporting the findings of this study are available within the article and the enrolled articles for meta-analysis.

The datasets generated and/or analyzed during the current study are available in PubMed, Embase, Web of Science (WOS), and Cochrane library repository.
PubMed: https://pubmed.ncbi.nlm.nih.gov/
Embase: https://www.embase.com/login
Web of Science: http://apps.webofknowledge.com
Cochrane Library: https://www.cochranelibrary.com/

Competing interests
The authors declare that they have no competing interests
Funding
This project was financially supported by the National Science Foundation of China (81472401 and 81772708), the Natural Science Foundation of Jiangsu Province (BK20190175), and the Science and Technology Project for the Youth of Suzhou (KJXW2018006).

Authors' contributions
HW and CC contributed equally to this work and shall share first authorship. Study design and basic data extraction: HW, CC, WZ and JH. Data extraction from the Kaplan–Meier curves: HW and CC. Third party evaluation: KD. Manuscript composition: HW and CC. All authors read and approved the final manuscript.

Acknowledgements
We sincerely thank Dr. Xiaojian Xu for his support in this study.

Reference:

1 Felekis, K., Touvana, E., Stefanou, C. and Deltas, C. (2010) microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 14, 236-240

2 Ling, H., Fabbri, M. and Calin, G. A. (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12, 847-865

3 Liu, H., Lei, C., He, Q., Pan, Z., Xiao, D. and Tao, Y. (2018) Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer. 17, 64

4 Liu, M., Zhang, Y., Zhang, J., Cai, H., Zhang, C., Yang, Z., Niu, Y., Wang, H., Wei, X.,
Wang, W., Gao, P., Li, H., Zhang, J. and Sun, G. (2018) MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A. Cell Death Dis. 9, 189

Zhuang, M., Qiu, X., Cheng, D., Zhu, C. and Chen, L. (2018) MicroRNA-524 promotes cell proliferation by down-regulating PTEN expression in osteosarcoma. Cancer Cell Int. 18, 114

Li, N., Long, B., Han, W., Yuan, S. and Wang, K. (2017) microRNAs: important regulators of stem cells. Stem Cell Res Ther. 8, 110

Song, L. and Tuan, R. S. (2006) MicroRNAs and cell differentiation in mammalian development. Birth Defects Res C Embryo Today. 78, 140-149

Pileczki, V., Cojocneanu-Petric, R., Maralani, M., Neagoe, I. B. and Sandulescu, R. (2016) MicroRNAs as regulators of apoptosis mechanisms in cancer. Clujul Med. 89, 50-55

Slattery, M. L., Mullany, L. E., Sakoda, L. C., Wolff, R. K., Samowitz, W. S. and Herrick, J. S. (2018) Dysregulated genes and miRNAs in the apoptosis pathway in colorectal cancer patients. Apoptosis. 23, 237-250

Bueno, M. J. and Malumbres, M. (2011) MicroRNAs and the cell cycle. Biochim Biophys Acta. 1812, 592-601

Mens, M. M. J. and Ghanbari, M. (2018) Cell Cycle Regulation of Stem Cells by MicroRNAs. Stem Cell Rev Rep. 14, 309-322

Shirjang, S., Mansoori, B., Asghari, S., Duijf, P. H. G., Mohammadi, A., Gjerstorff, M. and Baradaran, B. (2019) MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radic Biol Med. 139, 1-15

Abdelalim, E. M. (2013) Molecular mechanisms controlling the cell cycle in embryonic
stem cells. Stem Cell Rev Rep. 9, 764-773

14 Baranwal, S. and Alahari, S. K. (2010) miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126, 1283-1290

15 Kim, J., Yao, F., Xiao, Z., Sun, Y. and Ma, L. (2018) MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev. 37, 5-15

16 Lou, W., Liu, J., Gao, Y., Zhong, G., Shen, J., Bao, C., Xu, L., Pan, J., Cheng, J., Ding, B. and Fan, W. (2017) MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 8, 115787-115802

17 Du, J., Li, M., Huang, Q., Liu, W., Li, W. Q., Li, Y. J. and Gong, Z. C. (2019) The critical role of microRNAs in stress response: Therapeutic prospect and limitation. Pharmacol Res. 142, 294-302

18 Olejniczak, M., Kotowska-Zimmer, A. and Krzyzosiak, W. (2018) Stress-induced changes in miRNA biogenesis and functioning. Cell Mol Life Sci. 75, 177-191

19 Wiegand, C., Savelsbergh, A. and Heusser, P. (2017) MicroRNAs in Psychological Stress Reactions and Their Use as Stress-Associated Biomarkers, Especially in Human Saliva. Biomed Hub. 2, 1-15

20 Dupont, C., Kappeler, L., Saget, S., Grandjean, V. and Levy, R. (2019) Role of miRNA in the Transmission of Metabolic Diseases Associated With Paternal Diet-Induced Obesity. Front Genet. 10, 337

21 Huang, Y., Yan, Y., Xv, W., Qian, G., Li, C., Zou, H. and Li, Y. (2018) A New Insight into the Roles of MiRNAs in Metabolic Syndrome. Biomed Res Int. 2018, 7372636

22 Rottiers, V. and Naar, A. M. (2012) MicroRNAs in metabolism and metabolic disorders.
23 Lan, H., Lu, H., Wang, X. and Jin, H. (2015) MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015, 125094

24 Kang, H., Rho, J. G., Kim, C., Tak, H., Lee, H., Ji, E., Ahn, S., Shin, A. R., Cho, H. I., Huh, Y. H., Song, W. K., Kim, W. and Lee, E. K. (2017) The miR-24-3p/p130Cas: a novel axis regulating the migration and invasion of cancer cells. Sci Rep. 7, 44847

25 Yan, L., Ma, J., Zhu, Y., Zan, J., Wang, Z., Ling, L., Li, Q., Lv, J., Qi, S., Cao, Y., Liu, Y., Cao, L., Zhang, Y., Qi, Z. and Nie, L. (2018) miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7. J Cell Biochem. 119, 3989-3998

26 Du, W. W., Fang, L., Li, M., Yang, X., Liang, Y., Peng, C., Qian, W., O’Malley, Y. Q., Askeland, R. W., Sugg, S. L., Qian, J., Lin, J., Jiang, Z., Yee, A. J., Sefton, M., Deng, Z., Shan, S. W., Wang, C. H. and Yang, B. B. (2013) MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 126, 1440-1453

27 Khodadadi-Jamayran, A., Akgol-Oksuz, B., Afanasyeva, Y., Heguy, A., Thompson, M., Ray, K., Giro-Perafita, A., Sanchez, I., Wu, X., Tripathy, D., Zeleniuch-Jacquotte, A., Tsirigos, A. and Esteva, F. J. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget. 9, 12868-12878

28 Dong, X. and Liu, Y. (2018) Expression and significance of miR-24 and miR-101 in patients with advanced gastric cancer. Oncol Lett. 16, 5769-5774

29 Gao, Y., Liu, Y., Du, L., Li, J., Qu, A., Zhang, X., Wang, L. and Wang, C. (2015) Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Med
30 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J. and Moher, D. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339, b2700

31 Parmar, M. K., Torri, V. and Stewart, L. (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17, 2815-2834

32 Irwig, L., Macaskill, P., Berry, G. and Glasziou, P. (1998) Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 316, 470; author reply 470-471

33 Pan, Y., Wang, H., Ma, D., Ji, Z., Luo, L., Cao, F., Huang, F., Liu, Y., Dong, Y. and Chen, Y. (2018) miR24 may be a negative regulator of menin in lung cancer. Oncol Rep. 39, 2342-2350

34 Zhao, G., Liu, L., Zhao, T., Jin, S., Jiang, S., Cao, S., Han, J., Xin, Y., Dong, Q., Liu, X. and Cui, J. (2015) Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol. 36, 3693-3701

35 Zhou, N. and Yan, H. L. (2018) MiR-24 promotes the proliferation and apoptosis of lung carcinoma via targeting MAPK7. Eur Rev Med Pharmacol Sci. 22, 6845-6852

36 Liu, Y. X., Long, X. D., Xi, Z. F., Ma, Y., Huang, X. Y., Yao, J. G., Wang, C., Xing, T. Y. and Xia, Q. (2014) MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int. 2014, 482926

37 Meng, F. L., Wang, W. and Jia, W. D. (2014) Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol. 31, 177
38 Kerimis, D., Kontos, C. K., Christodoulou, S., Papadopoulos, I. N. and Scorilas, A. (2017) Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. Clin Biochem. 50, 285-292

39 Su, B., Xu, T., Bruce, J. P., Yip, K. W., Zhang, N., Huang, Z., Zhang, G., Liu, F. F., Liang, J., Yang, H. and Claret, F. X. (2018) hsamiR24 suppresses metastasis in nasopharyngeal carcinoma by regulating the cMyc/epithelialmesenchymal transition axis. Oncol Rep. 40, 2536-2546

40 Wang, S., Pan, Y., Zhang, R., Xu, T., Wu, W., Zhang, R., Wang, C., Huang, H., Calin, C. A., Yang, H. and Claret, F. X. (2016) Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5. Oncogene. 35, 6096-6108

41 Liu, L., Pan, J., Wang, H., Ma, Z., Yin, J., Yuan, F., Yuan, Q., Zhou, L., Liu, X., Zhang, Y., Bao, Z., Yang, H. and Ling, J. (2018) von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro. Biosci Rep. 38

42 Organista-Nava, J., Gomez-Gomez, Y., Illades-Aguilar, B., Del Carmen Alarcon-Romero, L., Saavedra-Herrera, M. V., Rivera-Ramirez, A. B., Garzon-Barrientos, V. H. and Leyva-Vazquez, M. A. (2015) High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia. Oncol Rep. 33, 1639-1649

43 Yan, Q., Chen, T., Yang, H., Yu, H., Zheng, Y., He, T. and Wang, J. (2019) The Effect of FERMT1 Regulated by miR-24 on the Growth and Radiation Resistance of Esophageal Cancer. J Biomed Nanotechnol. 15, 621-631

44 Mori, F., Ferraiuolo, M., Santoro, R., Sacconi, A., Goeman, F., Pallocca, M., Pulito, C.,
Korita, E., Fanciulli, M., Muti, P., Blandino, G. and Strano, S. (2016) Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget. 7, 20532-20548

45 Quan, J., Liu, S., Dai, K., Jin, L., He, T., Pan, X. and Lai, Y. (2018) MicroRNA-23a/24-2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta-analysis. Mol Clin Oncol. 8, 159-169

46 Royston, P. and Altman, D. G. (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 13, 33

47 Evangelou, E. and Ioannidis, J. P. (2013) Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 14, 379-389
### Table 1: Characteristics of studies included in this meta-analysis

| Study(year) | Country | Malignancy | Sample | Sample(F/M) | Assay | Survival | mRNA | HR (95% CI) | Follow-up | Cutoff-off-value NOS |
|-------------|---------|------------|--------|-------------|-------|----------|-------|-------------|-----------|---------------------|
| Meng et al. (2014) | China | HCC | Blood | 72(36/36) | qRT-PCR | OS/DFS | miR-24-3p | OS: 2.364(1.341–4.167) (Reported) 2.141(1.158–3.960) (Reported) DFS: 2.117(1.197–3.744) (Reported) 2.055(1.114–3.792) (Reported) | 60 | Median | 8 |
| Meng et al. (2014) | China | CRC | Tissue | 95(48/47) | qRT-PCR | OS | miR-24-3p | OS: 0.285(0.139–0.584) (Reported) 0.456(0.212–0.978) (Reported) | 60 | Median | 8 |
| Kerimis et al. (2017) | Greece | CRC | Tissue | 154(115/39) | qRT-PCR | OS/DFS | miR-24-3p | OS: 4.070(1.250–13.19) (Reported) 2.600(0.780–8.660) (Reported) DFS: 4.730(1.120–19.89) (Reported) 4.510 (1.050–19.33) (Reported) | 120 | 0.40RQU | 8 |
| Dong et al. (2018) | China | Advanced GC | Tissue | 247 ( NR ) | qRT-PCR | OS | miR-24 | OS: 2.945(1.344–4.575) (Reported) 3.162 (1.324–4.544) (Reported) | 15 | ΔΔCq=2 | 9 |
| Organista-NAVA et al. (2015) | Mexico | ALL | Marrow | 111(50/61) | qRT-PCR | OS | miR-24 | OS: 2.450(1.508–4.000) (U,K-M Curve) | about120 | 8.22fold(75p) | 7 |
| Organista-NAVA et al. (2015) | Mexico | AML | Marrow | 36(18/18) | qRT-PCR | OS | miR-25 | OS: 1.320(0.030–58.25) (U,K-M Curve) | about120 | 2.54fold(75p) | 7 |
| Su et al. (2018) | China | NPC | Tissue | 120(60/60) | qRT-PCR | OS | miR-24 | DMFS: 0.350(0.120–0.980) (Reported) | about168 | Median | 6 |
| Wang et al. (2016) | China | NPC | FFPE | 25(4/21) | qRT-PCR | RFS | miR-24-3p | RFS: 0.1800(0.020–1.660 ) (U,K-M Curve) | about117 | - | 6 |
| Liu et al. (2014) | China | HCC | Tissue | 207(116/91) | qRT-PCR | OS/DFS | miR-24 | OS: 2.860(1.650–4.970 ) (U,K-M Curve) 3.580(2.360–5.460) (Reported) RFS: 4.280(2.150–8.520 ) (U,K-M Curve) | 130 | - | 7 |
| Zhou et al. (2018) | China | Lung cancer | Tissue | 50(25/25) | qRT-PCR | OS | miR-24 | OS: 2.392 (0.400–14.45) (Reported) | 80 | Median | 8 |
| Mori et al. (2016) | Italy | HNSCC | Tissue | 108(52/56) | qRT-PCR | RFS | miR-24 | RFS: 1.770(1.040–3.300) (U,K-M Curve) | about70 | Median | 6 |
| Yan et al. (2019) | China | Esophageal cancer | Tissue | 86(34/52) | qRT-PCR | OS | miR-24 | OS: 0.540(0.210–1.350) (U,K-M Curve) | 20 | - | 5 |
| Zhao et al. (2015) | China | NSCLC | Tissue | 53(39/14) | qRT-PCR | RFS | miR-24-3p | RFS: 1.7400(0.390–7.200) (U,K-M Curve) | 30 | Median | 8 |
| Liu et al. (2018) | China | Osteoscarcoma | Tissue | 84(42/42) | qRT-PCR | OS | miR-24 | OS: 0.3100(0.160–0.630 ) (U,K-M Curve) | 50 | Median | 8 |
| Pan et al. (2018) | China | Lung cancer | Tissue | 70(41/29) | qRT-PCR | OS | miR-24 | OS: 3.570(1.390–9.150 ) (U,K-M Curve) | 60 | - | 8 |

**Note:** The dashes mean no data

HCC: Hepatocellular carcinoma, CRC: Colorectal cancer, Advanced GC: Advanced Gastric cancer, ALL: Acute Lymphocytic Leukemia, AML: Acute Myelocytic Leukemia, NPC: Nasopharyngeal carcinoma, HNSCC: Head and neck squamous cell carcinoma, NSCLC: Non-small cell lung carcinoma, OS: Overall survival, DFS: Disease-free survival, RFS: Recurrence-free survival, DMFS: Distant metastasis-free survival, NOS: Newcastle-Ottawa scale scores, U: univariate, M: multivariate
Table 2: Association between miR-24-3p expression levels and overall survivals

| Subgroups                | No. of studies | No. of patients | Pooled HR (95%CI) Fixed | Random | Meta regression p-value | Heterogeneity |
|--------------------------|----------------|-----------------|-------------------------|--------|-------------------------|---------------|
| Overall OS               | 11             | 1212            | 1.609(1.291-2.004)       | 1.507(0.810-2.803) | 85.20%       | ≤0.001        |
| Population Asian (Chinese) | 8              | 911             | 1.381(1.073-1.777)       | 1.271(0.585-2.762) | 0.341        | 88.50%        | ≤0.001        |
| Specimen Tissue          | 8              | 993             | 1.291(0.982-1.698)       | 1.336(0.574-3.108) | 0.505        | 88.40%        | ≤0.001        |
| Sample size ≥100         | 4              | 719             | 2.779(2.051-3.766)       | 2.779(2.051-3.766) | 0.069        | 0.000%        | ≥0.873        |
| Tumor Digestive system   | 6              | 700             | 1.078(0.771-1.507)       | 1.336(0.546-0.904) | 0.688        | 89.60%        | ≤0.001        |
| Tumor Solid tumor        | 9              | 1065            | 1.448(1.131-1.852)       | 1.427(0.687-2.960) | 0.675        | 87.50%        | ≤0.001        |
| Tumor Hematologic tumor  | 2              | 147             | 2.425(1.491-3.944)       | 2.425(1.491-3.944) | 0.000%       | 0.751         |               |
| Tumor Digestive system   | 6              | 945             | 1.705(1.291-2.253)       | 1.520(0.676-3.420) | 0.982        | 87.40%        | ≤0.001        |
| Tumor Non-Digestive system | 5             | 267             | 1.461(1.021-2.090)       | 1.505(0.466-4.863) | 0.850%       | 0.891         |               |
| Tumor Esophageal Cancer  | 1              | 86              | 0.540(0.210-1.350)       | 0.540(0.210-1.350) | —            | —             |               |
| Tumor Osteosarcoma       | 1              | 84              | 0.310(0.160-0.630)       | 0.310(0.160-0.630) | —            | —             |               |
| Tumor Gastric cancer     | 1              | 247             | 2.945(1.344-4.575)       | 2.945(1.344-4.575) | —            | —             |               |
| Tumor ALL                | 1              | 111             | 2.450(1.500-4.000)       | 2.450(1.500-4.000) | —            | —             |               |
| Tumor AML                | 1              | 36              | 1.320(0.030-58.25)       | 1.320(0.030-58.25) | —            | —             |               |
| Tumor Hepatocellular carcinoma | 2          | 279             | 2.607(1.756-3.871)       | 2.607(1.756-3.871) | 0.000%       | 0.637         |               |
| Tumor Lung cancer        | 2              | 120             | 3.274(1.422-7.539)       | 3.274(1.422-7.539) | 0.000%       | 0.698         |               |
| Tumor Colorectal cancer  | 2              | 249             | 0.585(0.317-1.080)       | 1.032(0.076-13.954) | 93.00%       | ≤0.001        |

Note: The dashes mean no data

95% CI: 95% confidence interval, Fixed: Fixed effects model, HR: hazard ratio, Random: Random pooling model
Table 3: Meta-analysis of miR-24-3p as an independent prognostic indicator for patients of various carcinomas

| Subgroups           | No. of studies | No. of patients | Pooled HR (95%CI) | Meta regression | Heterogeneity |
|---------------------|----------------|-----------------|-------------------|-----------------|---------------|
|                     |                |                 | Fixed             | Random          | p-value       |
| Overall             | 5              | 775             | 2.384(1.813-3.134) | 1.994(0.991-4.015) | 82.30%        |
| Population          |                |                 | 0.801             | 86.70%          | ≤0.001        |
| Asian (Chinese)     | 4              | 621             | 2.373(1.792-3.142) | 1.897(0.848-4.242) | —             |
| Non-Asian           | 1              | 154             | 2.600(0.780-8.660) | 2.600(0.780-8.660) | —             |
| Specimen            |                |                 | 0.932             | 86.60%          | ≤0.001        |
| Tissue              | 4              | 703             | 2.448(1.804-3.323) | 1.940(0.765-4.922) | —             |
| Blood               | 1              | 72              | 2.141(1.158-3.96)  | 2.141(1.158-3.96) | —             |
| Sample size         | ≥100           | 608             | 3.369(2.414-4.701) | 3.369(2.414-4.701) | 0.157         |
|                     | < 100          | 167             | 1.166(0.722-1.883) | 1.005(0.221-4.575) | 89.50%        |
| NOS                 | ≥8             | 496             | 1.593(1.020-2.488) | 1.530(0.402-5.818) | —             |
|                     | < 8            | 279             | 3.041(2.150-4.300) | 2.914(1.778-4.774) | 45.50%        |
| Tumor               | Colorectal cancer | 2         | 0.752(0.394-1.434) | 1.021(0.186-5.594) | —             |
|                     | Hepatocellular | 2              | 3.041(2.150-4.300) | 2.914(1.778-4.774) | 45.50%        |

Note: The dashes mean no data
95%CI: 95% confidence interval, Fixed: Fixed effects model, HR: hazard ratio, Random: Random pooling model
Table 4: Association between miR-24-3p expression levels and other prognostic indicators

|          | No. of studies | No. of patients | Pooled HR (95%CI)     | Heterogeneity |
|----------|----------------|----------------|-----------------------|---------------|
|          |                |                | Fixed                 | Random        | I²          | p-value |
| RFS      | Univariate     | 4              | 393                   | 2.315(1.491-3.594) | 1.814(0.741-4.440) | 66.70%   | 0.029   |
| DFS      | Univariate     | 2              | 226                   | 2.361(1.390-4.012) | 2.386(1.362-4.180) | 3.60%    | 0.309   |
|          | Multivariate   | 2              | 226                   | 2.313(1.315-4.067) | 2.313(1.315-4.067) | 0.000%   | 0.330   |

Note: The dashes mean no data

95%CI: 95% confidence interval, Fixed: Fixed effects model, HR: hazard ratio, Random: Random pooling model

Table 5: Overall analysis of miR-24-3p expression association with clinicopathological characteristics

| Clinicopathological parameters | No. of studies | No. of patients | Pooled OR (95%CI)     | Heterogeneity |
|-------------------------------|----------------|----------------|-----------------------|---------------|
|                               |                |                | Fixed                 | Random        | I²          | p-value |
| Gender                        | 5              | 329            | 1.286(0.758-2.107)   | 1.286(0.758-2.107) | 0.000%   | 0.842   |
| Age                           | 2              | 156            | 0.684(0.357-1.310)   | 0.684(0.357-1.310) | 0.000%   | 0.525   |
| Tumor size                    | 4              | 433            | 1.655(1.124-2.437)   | 1.605(0.985-2.689) | 37.50%   | 0.184   |
| Lymph node metastasis         | 2              | 120            | 1.591(0.758-3.339)   | 1.503(0.377-5.989) | 70.90%   | 0.064   |
| TNM stage                     | 5              | 486            | 1.437(0.959-2.154)   | 1.419(0.469-4.291) | 85.50%   | ≤0.001  |

Note: The dashes mean no data

95%CI: 95% confidence interval, Fixed: Fixed effects model, HR: hazard ratio, Random: Random pooling model

Figure titles and legends:

Figure 1: The flow chart of the meta-analysis

Figure 2: The association between miR-24-3p expression levels and the OS in patients of carcinoma. (A) overall survival, (B) overall survival without the outliers, (C) sensitivity analysis and (D) publication bias evaluation

Figure 3: Subgroup analyses for exploring the source of the heterogeneity between miR-24-3p expression levels and the OS. (A) population (Asian and Non-Asian), (B) sample sizes (<100 and ≥100), (C) NOS scores (<8 and ≥8), (D) specimen (Tissues and Non-Tissue), (E) tumor category1 (Solid tumor and...
Hematologic tumor), (F) tumor category2 (Digestive system and Non-Digestive system) for overall survival

**Figure 4:** The independent role of miR-24-3p as a prognostic indicator in patients of carcinoma. (A) overall survival, (B) overall survival without outliers, and (C) sensitivity analysis, (D) publication bias evaluation

**Figure 5:** The association between miR-24-3p expression levels and RFS in patients of carcinoma. (A) recurrence-free survival, (B) recurrence-free survival without the outliers as well as corresponding, (C) sensitivity analysis and (D) publication bias evaluation

**Figure 6:** The association between miR-24-3p expression level and TNM stages of cancer patients. (A) overall pooling result, (B) pooling result without the outliers, and (C) sensitivity analysis, (D) publication bias evaluation
Records identified through PubMed (n = 270)

Records identified through Emsbase (n = 429)

Records identified through WOS (n = 385)

Records identified through Cochrane library (n = 12)

Records after duplicates removal (n = 532)

Records excluded on title and abstract (n = 444)
- Not in English (n = 17)
- Review/meta-analysis (n = 154)
- Not related studies (n = 283)

Records about miR-24-3p in tumor (n = 86)

Records excluded (n = 72)
- Not on patients (n = 2)
- Without survival data (n = 45)
- Survival data from TCGA (n = 5)
- Multiple miRs (n = 1)
- Insufficient data (n = 19)

Records included meta-analysis (n = 14)
| ID       | Study                  | HR (95% CI)                  | Weight % | % Lower CI Limit | % Upper CI Limit |
|---------|------------------------|------------------------------|----------|------------------|------------------|
| Meng et al. (2014) | 2.34 (1.30, 4.27)     | 58.57 | 100 | 13.12 | 32.50 |
| Liu et al. (2010)   | 2.64 (1.85, 3.80)     | 15.91 | 100 | 0.28 | 0.39 |
| Gao et al. (2015)    | 2.35 (1.10, 4.70)     | 18.11 | 100 | 1.32 | 30.16 |
| Organista-NAVA et al. (2015) | 2.43 (0.48, 13.28)  | 12.00 | 100 | 0.30 | 0.90 |
| Kerimis et al. (2017) | 2.09 (1.06, 4.13)  | 12.00 | 100 | 0.39 | 0.90 |
| Pan et al. (2018)    | 3.57 (1.84, 6.90)     | 0.43  | 100 | 1.32 | 30.16 |
| Zhou et al. (2018)   | 2.38 (1.06, 5.40)     | 12.00 | 100 | 0.30 | 0.90 |
| Dong et al. (2010)   | 2.35 (0.48, 13.28)    | 12.00 | 100 | 0.39 | 0.90 |
| Liu et al. (2014)    | 0.51 (1.16, 2.13)     | 18.11 | 100 | 1.32 | 30.16 |
| Yan et al. (2019)    | 0.58 (1.12, 2.13)     | 3.00  | 100 | 1.32 | 30.16 |
| Overall (I-squared = 85.2%, p = 0.000) | 1.61 (1.29, 2.00) | 100.00 | 0.30 | 0.90 |

**Study**

| ID       | Study                  | HR (95% CI)                  | Weight % | % Lower CI Limit | % Upper CI Limit |
|---------|------------------------|------------------------------|----------|------------------|------------------|
| Meng et al. (2014) | 2.34 (1.30, 4.27)     | 58.57 | 100 | 13.12 | 32.50 |
| Liu et al. (2010)   | 2.64 (1.85, 3.80)     | 15.91 | 100 | 0.28 | 0.39 |
| Gao et al. (2015)    | 2.35 (1.10, 4.70)     | 18.11 | 100 | 1.32 | 30.16 |
| Organista-NAVA et al. (2015) | 2.43 (0.48, 13.28)  | 12.00 | 100 | 0.30 | 0.90 |
| Kerimis et al. (2017) | 2.09 (1.06, 4.13)  | 12.00 | 100 | 0.39 | 0.90 |
| Pan et al. (2018)    | 3.57 (1.84, 6.90)     | 0.43  | 100 | 1.32 | 30.16 |
| Zhou et al. (2018)   | 2.38 (1.06, 5.40)     | 12.00 | 100 | 0.30 | 0.90 |
| Dong et al. (2010)   | 2.35 (0.48, 13.28)    | 12.00 | 100 | 0.39 | 0.90 |
| Liu et al. (2014)    | 0.51 (1.16, 2.13)     | 18.11 | 100 | 1.32 | 30.16 |
| Yan et al. (2019)    | 0.58 (1.12, 2.13)     | 3.00  | 100 | 1.32 | 30.16 |
| Overall (I-squared = 85.2%, p = 0.000) | 1.61 (1.29, 2.00) | 100.00 | 0.30 | 0.90 |

**Begg’s funnel plot with pseudo 95% confidence limits**

**Study**

| ID       | Study                  | HR (95% CI)                  | Weight % | % Lower CI Limit | % Upper CI Limit |
|---------|------------------------|------------------------------|----------|------------------|------------------|
| Meng et al. (2014) | 2.34 (1.30, 4.27)     | 58.57 | 100 | 13.12 | 32.50 |
| Liu et al. (2010)   | 2.64 (1.85, 3.80)     | 15.91 | 100 | 0.28 | 0.39 |
| Gao et al. (2015)    | 2.35 (1.10, 4.70)     | 18.11 | 100 | 1.32 | 30.16 |
| Organista-NAVA et al. (2015) | 2.43 (0.48, 13.28)  | 12.00 | 100 | 0.30 | 0.90 |
| Kerimis et al. (2017) | 2.09 (1.06, 4.13)  | 12.00 | 100 | 0.39 | 0.90 |
| Pan et al. (2018)    | 3.57 (1.84, 6.90)     | 0.43  | 100 | 1.32 | 30.16 |
| Zhou et al. (2018)   | 2.38 (1.06, 5.40)     | 12.00 | 100 | 0.30 | 0.90 |
| Dong et al. (2010)   | 2.35 (0.48, 13.28)    | 12.00 | 100 | 0.39 | 0.90 |
| Liu et al. (2014)    | 0.51 (1.16, 2.13)     | 18.11 | 100 | 1.32 | 30.16 |
| Yan et al. (2019)    | 0.58 (1.12, 2.13)     | 3.00  | 100 | 1.32 | 30.16 |
| Overall (I-squared = 85.2%, p = 0.000) | 1.61 (1.29, 2.00) | 100.00 | 0.30 | 0.90 |

**Begg’s funnel plot with pseudo 95% confidence limits**

**Study**

| ID       | Study                  | HR (95% CI)                  | Weight % | % Lower CI Limit | % Upper CI Limit |
|---------|------------------------|------------------------------|----------|------------------|------------------|
| Meng et al. (2014) | 2.34 (1.30, 4.27)     | 58.57 | 100 | 13.12 | 32.50 |
| Liu et al. (2010)   | 2.64 (1.85, 3.80)     | 15.91 | 100 | 0.28 | 0.39 |
| Gao et al. (2015)    | 2.35 (1.10, 4.70)     | 18.11 | 100 | 1.32 | 30.16 |
| Organista-NAVA et al. (2015) | 2.43 (0.48, 13.28)  | 12.00 | 100 | 0.30 | 0.90 |
| Kerimis et al. (2017) | 2.09 (1.06, 4.13)  | 12.00 | 100 | 0.39 | 0.90 |
| Pan et al. (2018)    | 3.57 (1.84, 6.90)     | 0.43  | 100 | 1.32 | 30.16 |
| Zhou et al. (2018)   | 2.38 (1.06, 5.40)     | 12.00 | 100 | 0.30 | 0.90 |
| Dong et al. (2010)   | 2.35 (0.48, 13.28)    | 12.00 | 100 | 0.39 | 0.90 |
| Liu et al. (2014)    | 0.51 (1.16, 2.13)     | 18.11 | 100 | 1.32 | 30.16 |
| Yan et al. (2019)    | 0.58 (1.12, 2.13)     | 3.00  | 100 | 1.32 | 30.16 |
| Overall (I-squared = 85.2%, p = 0.000) | 1.61 (1.29, 2.00) | 100.00 | 0.30 | 0.90 |

**Begg’s funnel plot with pseudo 95% confidence limits**
**A**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Annunziata (2014) | 3.66 (1.34, 9.67) | 15.00 |
| Jin et al. (2018) | 2.96 (1.60, 4.69) | 19.92 |
| Gao et al. (2013) | 1.21 (0.48, 3.19) | 9.11 |
| Pan et al. (2015) | 0.75 (0.40, 1.42) | 6.60 |
| Zhu et al. (2018) | 2.70 (1.63, 4.11) | 15.00 |
| Dong et al. (2018) | 2.58 (1.63, 4.11) | 12.00 |
| Li et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Yan et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 3.65 (2.02, 6.63) | 27.97 |

**B**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Gao et al. (2013) | 3.66 (1.34, 9.67) | 15.00 |
| Gao et al. (2013) | 2.96 (1.60, 4.69) | 19.92 |
| Pan et al. (2015) | 1.21 (0.48, 3.19) | 9.11 |
| Jia et al. (2018) | 0.75 (0.40, 1.42) | 6.60 |
| Zhu et al. (2018) | 2.70 (1.63, 4.11) | 15.00 |
| Dong et al. (2018) | 2.58 (1.63, 4.11) | 12.00 |
| Li et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Yan et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 3.65 (2.02, 6.63) | 27.97 |

**C**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Ming et al. (2014) | 2.96 (1.60, 4.69) | 15.00 |
| Jin et al. (2018) | 2.58 (1.63, 4.11) | 12.00 |
| Gao et al. (2013) | 0.18 (0.09, 0.35) | 10.38 |
| Karavas et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Pan et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Zhu et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Dong et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Li et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 2.96 (1.60, 4.69) | 15.00 |

**D**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Jia et al. (2018) | 2.96 (1.60, 4.69) | 15.00 |
| Pan et al. (2015) | 1.21 (0.48, 3.19) | 9.11 |
| Zhu et al. (2018) | 0.75 (0.40, 1.42) | 6.60 |
| Dong et al. (2018) | 2.70 (1.63, 4.11) | 15.00 |
| Li et al. (2019) | 2.58 (1.63, 4.11) | 12.00 |
| Yan et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 2.96 (1.60, 4.69) | 15.00 |

**E**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Ming et al. (2014) | 2.96 (1.60, 4.69) | 15.00 |
| Jin et al. (2018) | 2.58 (1.63, 4.11) | 12.00 |
| Gao et al. (2013) | 0.18 (0.09, 0.35) | 10.38 |
| Karavas et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Pan et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Zhu et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Dong et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Li et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 2.96 (1.60, 4.69) | 15.00 |

**F**

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Ming et al. (2014) | 2.96 (1.60, 4.69) | 15.00 |
| Jin et al. (2018) | 2.58 (1.63, 4.11) | 12.00 |
| Gao et al. (2013) | 0.18 (0.09, 0.35) | 10.38 |
| Karavas et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Pan et al. (2015) | 0.18 (0.09, 0.35) | 10.38 |
| Zhu et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Dong et al. (2018) | 0.18 (0.09, 0.35) | 10.38 |
| Li et al. (2019) | 0.18 (0.09, 0.35) | 10.38 |
| Subtotal (1-adjusted): 0.0% (p = 0.000) | 2.96 (1.60, 4.69) | 15.00 |
Overall (I-squared = 82.3%, p = 0.000)

Gao et al. (2015)
Dong et al. (2018)
Kerimis et al. (2017)
Liu et al. (2014)
Meng et al. (2014)

| Study          | HR (95% CI) | Weight |
|----------------|-------------|--------|
| Meng et al. (2014) | 2.14 (1.16, 3.96) | 19.40  |
| Liu et al. (2014)   | 3.58 (2.55, 5.45) | 42.55  |
| Gao et al. (2015)   | 0.46 (0.21, 0.99) | 12.81  |
| Kerimis et al. (2017)| 2.60 (0.78, 8.66) | 5.17   |
| Dong et al. (2018)  | 3.16 (1.71, 5.86) | 19.68  |
| Overall (I-squared = 82.3%, p = 0.000) | 2.38 (1.81, 3.13) | 100.00 |

- **B**: Meta-analysis estimates, given named study is omitted
- **C**: Meta-analysis estimates, given named study is omitted
- **D**: Egger’s funnel plot with pseudo 95% confidence limits
| Study            | HR (95% CI) | Weight |
|------------------|-------------|--------|
| Mori et al. (2016) | 2.31 (1.49, 3.59) | 100.00 |
| Liu et al. (2014)  | 1.77 (0.93, 3.38)  | 3.96  |
| Wang et al. (2016) | 1.74 (0.80, 3.56)  | 14.29 |
| Mori et al. (2016) | 1.77 (0.93, 3.38)  | 14.29 |
| Overall (I-squared = 66.7%, p = 0.029) | 2.31 (1.49, 3.38)  | 100.00 |

| Study            | HR (95% CI) | Weight |
|------------------|-------------|--------|
| Mori et al. (2016) | 2.57 (1.64, 4.03) | 48.01 |
| Liu et al. (2014)  | 1.74 (0.40, 7.48)  | 4.01  |
| Wang et al. (2016) | 4.28 (2.15, 8.52)  | 9.48  |
| Mori et al. (2016) | 1.77 (0.93, 3.38)  | 9.48  |
| Overall (I-squared = 45.3%, p = 0.161) | 2.37 (1.44, 4.03)  | 100.00 |

**Meta-analysis estimates, given named study is omitted**

**Begg's funnel plot with pseudo 95% confidence limits**
## Table

| Study            | HR (95% CI)     | Weight |
|------------------|-----------------|--------|
| Meng et al. (2014) | 3.13 (1.13, 8.71) | 19.63  |
| Liu et al. (2014)  | 1.35 (0.96, 1.94) | 40.26  |
| Zhao et al. (2015) | 1.60 (0.47, 5.47) | 10.81  |
| Pan et al. (2018)  | 3.13 (1.13, 8.71) | 15.47  |
| Liu et al. (2018)  | 0.16 (0.06, 0.41) | 17.84  |
| Overall (I-squared = 85.5%, p = 0.000) | 1.44 (0.96, 2.15) | 100.00 |

## Diagram

### A

- Meta-analysis estimates, given named study is omitted
- Overall (I-squared = 85.5%, p = 0.000)

### B

- Begg's funnel plot with pseudo 95% confidence limits
- Overall (I-squared = 0.0%, p = 0.502)